Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Short Interest Update

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) was the target of a significant drop in short interest during the month of October. As of October 31st, there was short interest totalling 10,800 shares, a drop of 6.9% from the October 15th total of 11,600 shares. Based on an average daily trading volume, of 8,500 shares, the days-to-cover ratio is currently 1.3 days. Currently, 0.1% of the shares of the company are sold short.

Analyst Upgrades and Downgrades

Separately, Benchmark reaffirmed a “speculative buy” rating and set a $8.00 price target on shares of Anebulo Pharmaceuticals in a research report on Tuesday, October 1st.

Anebulo Pharmaceuticals Stock Down 3.7 %

NASDAQ ANEB opened at $1.53 on Tuesday. The firm has a market cap of $39.67 million, a P/E ratio of -5.10 and a beta of -1.00. The company’s 50 day moving average is $1.90 and its 200-day moving average is $2.11. Anebulo Pharmaceuticals has a 12-month low of $1.46 and a 12-month high of $3.30.

Anebulo Pharmaceuticals (NASDAQ:ANEB) last issued its earnings results on Wednesday, September 25th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.08. Equities analysts expect that Anebulo Pharmaceuticals will post -0.52 EPS for the current year.

About Anebulo Pharmaceuticals

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.